The effect of RG 12525 on leukotriene D4-mediated pulmonary responses in guinea pigs

@article{Carnathan2005TheEO,
  title={The effect of RG 12525 on leukotriene D4-mediated pulmonary responses in guinea pigs},
  author={Gilbert W. Carnathan and D M Sweeney and Jeffery J. Travis and Richard G. Van Inwegen},
  journal={Agents and Actions},
  year={2005},
  volume={27},
  pages={316-318}
}
RG 12525 (5-(2-[4-quinolin-2-yl)methoxy] phenoxymethyl)benzyl tetrazole) is under investigation as a specific inhibitor of leukotriene D4 (LTD4). The present studies examine the effect of orally administered RG 12525 on LTD4 mediated pulmonary responses in three separate guinea pig models. The compound inhibited antigen-induced mortality in the systemic anaphylaxis model with an ED50 (95% confidence interval)=2.2 (0.8–6.4) mg/kg. In this model, the activity half-life of RG 12525 was shown to be… 

References

SHOWING 1-8 OF 8 REFERENCES
REV 5901: an orally effective peptidoleukotriene antagonist, detailed biochemical/pharmacological profile.
TLDR
In addition to its previously reported activity as a 5-lipoxygenase inhibitor, REV 5901 is a p.o. active antagonist of peptidoleukotrienes and represents a good tool for understanding the role of peptinolinylmethoxy in disease.
SKF 104353, a high affinity antagonist for human and guinea pig lung leukotriene D4 receptor, blocked phosphatidylinositol metabolism and thromboxane synthesis induced by leukotriene D4.
TLDR
It is demonstrated that SKF 104353 is a high affinity, specific LTD4 receptor antagonist that inhibited LTD4-induced PI hydrolysis and TxB2 biosynthesis in guinea pig lung and of value therapeutically in the treatment of leukotriene-mediated diseases.
In vitro pharmacology of ICI 198,615: a novel, potent and selective peptide leukotriene antagonist.
TLDR
In vitro studies indicate that ICI 198,615 is the most potent and selective peptide LT receptor antagonist described to date.
Increased concentrations of leukotrienes in bronchoalveolar lavage fluid of patients with ARDS or at risk for ARDS.
TLDR
Increased amounts of LTs in BAL fluid are a general finding in patients with ARDS and those "at risk" for ARDS, and the sulfidopeptide LTs correlated with BAL fluid protein content.
In vivo pharmacology of ICI 198,615: a novel, potent and selective peptide leukotriene antagonist.
TLDR
Results indicate that ICI 198,615 possesses an in vivo profile which is consonant with utility in the treatment of allergic diseases, and is less able to reverse the effect of LTD4 on Cdyn.
Leukotrienes as mediators of airway anaphylaxis.
An orally effective peptido - leukotriene antagonist , detailed biochemical / pharmacological profile
  • J . Pharmac . Exp . Thera .
  • 1987
RG 12525 and related compounds , a new orally active series of leukotriene antagonists
  • The Pharmacologist
  • 1988